HPV16 Ct-DNA dosing

Phase 2Biologic

UUNICANCER

HPV16 Ct-DNA dosing is one of 16 biologic programs targeting Oropharyngeal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oropharyngeal CancerRecruiting

Oropharyngeal CancerPhase 2

Recruiting

Competition

Competitive Landscape

19 competitors in Oropharyngeal Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

1 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 3

Taxol

Teva

Phase 2

3 4

Beyfortus

BeiGene

Phase 2

1 5

Paraplatin

AAvyxa

Phase 2

4 6

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

1 7

Fludara

Sanofi

Phase 1

1 8

Balstilimab

AAgenus Inc.

Phase 2

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 10

Xentuzumab

SSyndax Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Recruiting

Oropharyngeal Cancer

NCT05582122

Clinical

Trials by Indication[1]

Oropharyngeal Cancer1 trial

SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers

Recruiting·UUNICANCER·Phase 2·NCT05582122·420 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HPV16 Ct-DNA dosing. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HPV16 Ct-DNA dosing compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HPV16 Ct-DNA dosing. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNICANCER company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUNICANCER

HPV16 Ct-DNA dosing

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Oropharyngeal Cancer1 trial

References

Drug Info

Quick Facts

Related News